



5-Amino-1MQ is a small molecule, not a peptide. It inhibits nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide using SAM as the methyl donor and sends the product, 1-methylnicotinamide, out of the NAD+ salvage pathway. In cultured adipocytes, methylquinolinium inhibitors of this class lowered 1-methylnicotinamide, raised intracellular NAD+ and SAM, and suppressed lipogenesis, and they did not inhibit the related SAM-dependent methyltransferases or the other salvage-pathway enzymes that were tested. That selectivity, plus membrane permeability measured in artificial-membrane and Caco-2 assays, is what makes the scaffold a practical bench tool. Researchers use it to ask what happens to NAD+ availability, methylation chemistry and adipocyte metabolism when NNMT is switched off rather than when NAD+ precursors are added.
Structured specifications and handling data
Technical specifications
C10H11N2+Stability and handling
Compounds commonly studied alongside this one.
NNMT takes nicotinamide, a form of vitamin B3, and attaches a methyl group to it using SAM (S-adenosylmethionine) as the donor. The product, 1-methylnicotinamide, cannot be recycled back into NAD+ through the salvage pathway, so an active NNMT drains two things at once: the nicotinamide a cell could have turned into NAD+, and the methyl groups it needs for everything else that uses SAM. 5-Amino-1MQ blocks the enzyme, so both pools stay fuller.
In 3T3-L1 adipocytes, inhibitors of this methylquinolinium series lowered 1-methylnicotinamide, raised intracellular NAD+ and SAM, and suppressed lipogenesis. The same work tested the compounds against structurally related methyltransferases and against the NAD+ salvage enzymes and found no inhibition, which is why the scaffold is used to attribute an effect specifically to NNMT rather than to methyl metabolism in general.
What NNMT itself responds to is also an active question. In cultured adipocytes, glucose deprivation doubled NNMT mRNA and protein, and AMPK activation or mTOR inhibition reproduced the effect, which places the enzyme downstream of the cell's own energy sensing. Animal work has gone in a different direction: in aged mice, NNMT inhibition raised grip strength, and the effect added to exercise rather than overlapping with it, and in a mouse model of hindlimb ischemia it improved muscle strength without changing perfusion or capillary density. Those are rodent and cell-culture endpoints, and the compound has no published human trials.
Published studies and concise summaries for research review.
AI-generated summary of this research paper below.
Concise answers about laboratory context, handling, and documentation for this compound.
Laboratory compliance notice
All compounds sold by Validated Peptides are intended for in-vitro laboratory research only.
These materials are not approved by the FDA for human or animal use and are not intended for diagnostic, therapeutic, or clinical applications.
Purchasers are responsible for compliant handling, storage, and use within an appropriate laboratory environment.